SMARCB1 and rhabdoid tumor: We left TP53 in the analysis for two reasons: (1) to remain unbiased, as the Catalogue of Somatic Mutations In Cancer (COSMIC) identified it as a potential oncogene in some cancer contexts, and (2) based on specific observations in SMARCB1-deficient rhabdoid tumors which show that TP53 is a synthetic lethal target.26